Editorial Team
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Editorial Team | Published : September 17, 2018 11:47 AM IST
Anil Kumble graces the National Insulin Summit.
The National Insulin Summit, one of India's most prestigious medical symposiums, conducted by Diabetes Research Society (DIABAID) and supported by Novo Nordisk, the world leader in diabetes care was inaugurated by leading endocrinologists.
Dr A K Das, National Convenor, 12th NIS, expressing his concerns over the growing diabetes epidemic said that Indians are genetically predisposed towards diabetes. A high carb diet, obesity due to lifestyle changes and the impact of urbanization and globalisation have led to a rapid rise of diabetes in India. In India, almost 58% of people with diabetes remain undetected. Hence many patients have micro-vascular and macro-vascular complications present already at the time of diagnosis.
The theme of this NIS was 'ImpACTing diabetes together.' The need of the hour is to join the fight against diabetes for a healthy India. The 12th edition of the National Insulin Summit (NIS) was special as for the first time a patient interaction session helmed by cricketer Anil Kumble, changing diabetes ambassador was held under the aegis of Novo Nordisk Education Foundation. Two people with diabetes- a seven-year-old child with type 1 diabetes and a 70-year old adult with type 2 diabetes for over 3 decades- shared their life story and how they overcame challenges associated with diabetes.
Sharing his experience as changing diabetes ambassador, Anil Kumble said that over the last 1.5 years, he has been fortunate to have met real-life champions who are living with diabetes with a smile. He also mentioned that it's inspiring to see these people managing their diabetes well.
The NIS with a congregation of more than 300 experts in the field of diabetes from across India saw discussions, deliberations and presentations on various aspects of diabetes management and insulin therapy. Mr Melvin D'souza, Managing Director, Novo Nordisk India said that Novo Nordisk is committed to creating awareness about diabetes and enabling people with diabetes are provided with the best-in-class quality medication. And with over 72 million people with diabetes in India2, we recognise there is a need for stakeholders to collectively address this emergency. The National Insulin Summit is the right platform for doctors to come together to deliberate the advancements in diabetes care treatment and best practices. We are happy to support DIABAID in their initiative of creating a platform to ideate, debate and share scientific updates on diabetes.
Insulin remains the only treatment for glucose regulation in type 1 diabetes patients and is often the crucial element in any treatment management plan for advanced type 2 diabetes. Some of the results of late or inadequate treatment of diabetes include complications such as heart disease, hypertension, kidney failure, diabetic retinopathy and even death. However, early and appropriate use of insulin can not only prevent short-term complications but also reduce long-term morbidity and mortality.
